-
1 Comment
SMS Lifesciences India Limited is currently in a long term uptrend where the price is trading 25.0% above its 200 day moving average.
From a valuation standpoint, the stock is 85.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
SMS Lifesciences India Limited's total revenue rose by 42.9% to $666M since the same quarter in the previous year.
Its net income has increased by 894.7% to $27M since the same quarter in the previous year.
Finally, its free cash flow fell by 118.9% to $-13M since the same quarter in the previous year.
Based on the above factors, SMS Lifesciences India Limited gets an overall score of 4/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | INE320X01016 |
| CurrencyCode | INR |
| Exchange | NSE |
| PE Ratio | 8.77 |
|---|---|
| Market Cap | 2B |
| Beta | 0.9 |
| Dividend Yield | 0.3% |
| Target Price | None |
SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers APIs in various therapeutic areas, such as antiulcer, antifungal, erectile dysfunction, anti-gout, anesthesia, anti-infective, anti-obesity, anti-convulsant, anti-emetic, ophthalmic, anti-worm, and antiemetic. The company also exports its products. SMS Lifesciences India Limited was founded in 1990 and is based in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SMSLIFE.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
